Diagnosis of melanoma and solar lentigo by nucleic acid analysis
AssigneeDermTech International
InventorSherman H. Chang
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for diagnosing melanoma and/or solar lentigo in a subject by analyzing nucleic acid molecules obtained from the subject. The present invention also provides methods for distinguishing melanoma from solar lentigo and/or dysplastic nevi and/or normal pigmented skin. The methods include analyzing expression or mutations in epidermal samples, of one or more skin markers. The methods can include the use of a microarray to analyze gene or protein profiles from a sample
Claims20
A method of distinguishing melanoma from dysplastic nevi or normal pigmented skin in a human subject comprising:
- (a) obtaining a sample of a skin lesion from a human subject;
- (b) analyzing expression of a nucleic acid molecule encoding a protein selected from among:
- endothelin receptor type B;
- Hypothetical protein MGC40222;
- tetratricopeptide repeat domain 3;
- staufen, RNA binding protein (Drosophila);
- actinin, alpha 4;
- KIAA1212;
- glycoprotein M6B;
- v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;
- c-Maf-inducing protein;
- adaptor-related protein complex 2, mu 1 subunit;
- syntaxin 5A;
- chemokine-like factor superfamily 4;
- UDP-Gal:
- betaGlcNAc beta 1,4-galactosyl-transferase, polypeptide 5;
- fibrosin 1;
- ortholog of mouse neighbor of Punc E11;
- myosin, heavy polypeptide 14;
- preferentially expressed antigen in melanoma;
- jumonji domain containing 3;
- BCL2-related protein A1;
- formin binding protein 1, and combinations thereof, in the sample;
- and
- (c) characterizing the skin lesion as being melanoma, dysplastic nevi, or normal pigmented skin, thereby distinguishing melanoma from dysplastic nevi or normal pigmented skin in a human subject.
A method for diagnosing melanoma in a subject, comprising:
- (a) providing a gene expression profile of a target area suspected of being melanoma on the skin of the subject, wherein the target area of the skin simultaneously expresses a plurality of genes at the protein level that are markers for melanoma;
- and
- (b) analyzing the subject's gene expression profile to a reference gene expression profile obtained from a corresponding normal skin sample, wherein the reference gene expression profile comprises an expression value of a target gene that encodes a protein selected from the group consisting of:
- endothelin receptor type B;
- Hypothetical protein MGC40222;
- tetratricopeptide repeat domain 3;
- staufen, RNA binding protein (Drosophila);
- actinin, alpha 4;
- KIAA1212;
- glycoprotein M6B;
- v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;
- c-Maf-inducing protein;
- adaptor-related protein complex 2, mu 1 subunit;
- syntaxin 5A;
- chemokine-like factor superfamily 4;
- UDP-Gal:
- betaGlcNAc beta 1,4-galactosyl-transferase, polypeptide 5;
- fibrosin 1;
- ortholog of mouse neighbor of Punc E11;
- myosin, heavy polypeptide 14;
- preferentially expressed antigen in melanoma;
- jumonji domain containing 3;
- BCL2-related protein A1;
- formin binding protein 1;
- or any combination thereof.
A kit for characterizing a skin lesion in a subject comprising a skin sample collection device and one or more probes or primers that selectively bind to a nucleic acid molecule encoding a protein selected from among:
- endothelin receptor type B;
- Hypothetical protein MGC40222;
- tetratricopeptide repeat domain 3;
- staufen, RNA binding protein (Drosophila);
- actinin, alpha 4;
- KIAA1212;
- glycoprotein M6B;
- v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;
- c-Maf-inducing protein;
- adaptor-related protein complex 2, mu 1 subunit;
- syntaxin 5A;
- chemokine-like factor superfamily 4;
- UDP-Gal:
- betaGlcNAc beta 1,4-galactosyl-transferase, polypeptide 5;
- fibrosin 1;
- ortholog of mouse neighbor of Punc E11;
- myosin, heavy polypeptide 14;
- preferentially expressed antigen in melanoma;
- jumonji domain containing 3;
- BCL2-related protein A1;
- and formin binding protein 1.
Dependencies are inferred from the claim text.